3-<2-Chlor-phenyl>-1-methyl-pyrrolidin | 91131-01-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-<2-Chlor-phenyl>-1-methyl-pyrrolidin
• 英文别名: 3-(2-chloro-phenyl)-1-methyl-pyrrolidine；3-(2-Chlorophenyl)-1-methylpyrrolidine
• CAS: 91131-01-0
• 化学式: C₁₁H₁₄ClN
• 分子量: 195.692
• InChiKey: IQJLAVTULNFDLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION
  申请人：Sonesson Clas

  公开号：US20100179211A1

  公开（公告）日：2010-07-15

  The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.

  本发明涉及利用增加哺乳动物大脑脑皮层区域儿茶酚胺、多巴胺和去甲肾上腺素的细胞外水平的化合物，更具体地涉及利用3-二取代苯基-1-吡咯烷醇治疗中枢神经系统疾病。
• Novel Compounds as Serine Protease Inhibitors
  申请人：Zimmermann Kaspar

  公开号：US20100076024A1

  公开（公告）日：2010-03-25

  The invention relates to compounds of formula (I) wherein the substituents are as defined in claim 1 ; to compositions comprising said compounds and to their use as pharmaceutical agents, in particular as inhibitors of serine proteases.

  本发明涉及式(I)的化合物，其中取代基如权利要求1所定义；涉及包含该化合物的组合物以及它们作为药物的使用，特别是作为丝氨酸蛋白酶的抑制剂。
• TRICYCLIC HETEROCYCLIC COMPOUNDS
  申请人：Dhar T.G. Murali

  公开号：US20120214767A1

  公开（公告）日：2012-08-23

  Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X 1 , X 2 , X 3 , W, Q 1 , Q 2 , and G 2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及公式（I）的化合物或其立体异构体或盐，其中：X1、X2、X3、W、Q1、Q2和G2在此定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面有用，例如自身免疫性疾病和血管疾病。
• NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION
  申请人：NSAB, Filial af NeuroSearch Sweden AB, Sverige

  公开号：EP2155669B1

  公开（公告）日：2011-05-04
• Tricyclic heterocyclic compounds
  申请人：Bristol-Myers Squibb Company

  公开号：EP2592071B1

  公开（公告）日：2019-09-18